The FDA granted approval to Brinsuprí (brensocatib), an oral DPP1 inhibitor developed by Insmed for treating non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older. This marks the first and only FDA-approved therapy directly targeting neutrophilic inflammation, a root cause of disease exacerbations. The drug demonstrated efficacy in reducing lung damage and decline in lung function, providing a new option for approximately 500,000 U.S. patients living with NCFB.